{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:39:01Z","timestamp":1793299141868,"version":"4.5.0"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.metabol.2023.155741","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:35:03Z","timestamp":1700642103000},"page":"155741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond"],"prefix":"10.1016","volume":"151","author":[{"given":"Dimitrios","family":"Tsilingiris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kokkinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2023.155741_bb0005","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.metabol.2023.155741_bb0010","article-title":"Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis","volume":"359","author":"Ma","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2023.155741_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121993","article-title":"Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials","volume":"10","author":"Kritchevsky","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2023.155741_bb0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ekir.2017.01.010","article-title":"Bariatric surgery and kidney-related outcomes","volume":"2","author":"Chang","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.metabol.2023.155741_bb0025","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/eurheartj\/ehac071","article-title":"Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis","volume":"43","author":"van Veldhuisen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2023.155741_bb0030","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa1700459","article-title":"Weight and metabolic outcomes 12\u00a0years after gastric bypass","volume":"377","author":"Adams","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5934","article-title":"Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials","volume":"347","author":"Gloy","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2023.155741_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053242","article-title":"Comparing effects of obesity treatment with very low energy diet and bariatric surgery after 2\u00a0years: a prospective cohort study","volume":"12","author":"Hoskuldsdottir","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.metabol.2023.155741_bb0045","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s11695-018-3163-6","article-title":"Which bariatric procedure is the most popular in the world? A bibliometric comparison","volume":"28","author":"Ozsoy","year":"2018","journal-title":"Obes Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0050","first-page":"129","article-title":"Bariatric surgery for severe obesity","volume":"12","author":"Sugerman","year":"2001","journal-title":"J Assoc Acad Minor Phys"},{"key":"10.1016\/j.metabol.2023.155741_bb0055","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.soard.2018.03.003","article-title":"Mechanisms in bariatric surgery: gut hormones, diabetes resolution, and weight loss","volume":"14","author":"Holst","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.metabol.2023.155741_bb0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/nyas.13409","article-title":"Mechanisms of weight loss and improved metabolism following bariatric surgery","volume":"1411","author":"Mulla","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2023.155741_bb0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1466-5468.2004.1180h.x","article-title":"Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes","volume":"21","author":"Rachman","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ijo.2013.205","article-title":"Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?","volume":"38","author":"Miras","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.metabol.2023.155741_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/nu13020351","article-title":"Incretin hormones in obesity and related cardiometabolic disorders: the clinical perspective","volume":"13","author":"Michalowska","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2023.155741_bb0080","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2023.155741_bb0085","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1463-1326.2011.01549.x","article-title":"Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity","volume":"14","author":"Knop","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0090","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients","volume":"57","author":"Muscelli","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2023.155741_bb0095","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.clnu.2022.07.001","article-title":"Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity","volume":"41","author":"Perakakis","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.metabol.2023.155741_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/nu12020476","article-title":"Enhanced GIP secretion in obesity is associated with biochemical alteration and miRNA contribution to the development of liver steatosis","volume":"12","author":"Goralska","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2023.155741_bb0105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/jc.2010-1605","article-title":"Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects","volume":"96","author":"Hansen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0110","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa061","article-title":"Oxyntomodulin and glicentin may predict the effect of bariatric surgery on food preferences and weight loss","volume":"105","author":"Nielsen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.153997","article-title":"Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: evidence from two independent trials","volume":"101","author":"Perakakis","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155741_bb0120","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.celrep.2019.01.047","article-title":"Important role of the GLP-1 axis for glucose homeostasis after bariatric surgery","volume":"26","author":"Larraufie","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.metabol.2023.155741_bb0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1152\/physrev.00031.2014","article-title":"Ghrelin, CCK, GLP-1, and PYY(3\u201336): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB","volume":"97","author":"Steinert","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2023.155741_bb0130","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.soard.2007.08.004","article-title":"Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding","volume":"3","author":"Korner","year":"2007","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.metabol.2023.155741_bb0135","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/01.sla.0000133117.12646.48","article-title":"The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism","volume":"240","author":"Rubino","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1753-0407.2009.00064.x","article-title":"Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery","volume":"2","author":"Bose","year":"2010","journal-title":"J Diabetes"},{"key":"10.1016\/j.metabol.2023.155741_bb0145","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jpen.2286","article-title":"Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel","volume":"46","author":"Reiner","year":"2022","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.metabol.2023.155741_bb0150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/nyas.14791","article-title":"The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel","volume":"1514","author":"Reiner","year":"2022","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.metabol.2023.155741_bb0155","doi-asserted-by":"crossref","first-page":"E708","DOI":"10.1210\/jc.2012-3736","article-title":"Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids","volume":"98","author":"Kohli","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0160","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/oby.2009.102","article-title":"Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism","volume":"17","author":"Patti","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2023.155741_bb0165","doi-asserted-by":"crossref","first-page":"E660","DOI":"10.1002\/oby.20522","article-title":"Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial","volume":"21","author":"Steinert","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2023.155741_bb0170","article-title":"Intestinal co-culture system to study TGR5 Agonism and gut restriction","volume":"11","author":"Chaudhari","year":"2021","journal-title":"Bio Protoc"},{"key":"10.1016\/j.metabol.2023.155741_bb0175","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.01.139","article-title":"Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1","volume":"329","author":"Katsuma","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2023.155741_bb0180","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jceh.2019.09.005","article-title":"Natural history of simple steatosis or nonalcoholic fatty liver","volume":"10","author":"De","year":"2020","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.metabol.2023.155741_bb0185","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.metabol.2023.155741_bb0190","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s11695-020-05084-0","article-title":"Efficacy and safety of intragastric balloon (IGB) in non-alcoholic fatty liver disease (NAFLD): a comprehensive review and meta-analysis","volume":"31","author":"Chandan","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0195","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/SLA.0000000000000945","article-title":"Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study","volume":"260","author":"Caiazzo","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.suc.2016.03.008","article-title":"The effects of metabolic surgery on fatty liver disease and nonalcoholic steatohepatitis","volume":"96","author":"Clanton","year":"2016","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.metabol.2023.155741_bb0205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2023.155741_bb0210","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2023.155741_bb0215","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0220","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.32358","article-title":"Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery","volume":"76","author":"Pais","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155741_bb0225","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric surgery and long-term cardiovascular events","volume":"307","author":"Sjostrom","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0230","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s11695-021-05849-1","article-title":"Long-term impact of bariatric surgery on major adverse cardiovascular events in patients with obesity, diabetes and hypertension: a population-level study","volume":"32","author":"Bouchard","year":"2022","journal-title":"Obes Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0235","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2022.01.047","article-title":"Long-term cardiovascular outcomes after bariatric surgery in the Medicare population","volume":"79","author":"Mentias","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2023.155741_bb0240","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.soard.2022.12.025","article-title":"Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis","volume":"19","author":"Wang","year":"2023","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.metabol.2023.155741_bb0245","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.amjsurg.2019.09.006","article-title":"Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: a propensity matched analysis","volume":"219","author":"Kwak","year":"2020","journal-title":"Am J Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0250","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery","volume":"18","author":"Eisenberg","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.metabol.2023.155741_bb0255","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1007\/s11695-021-05374-1","article-title":"Factors associated with favorable changes in food preferences after bariatric surgery","volume":"31","author":"Nielsen","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0260","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa329","article-title":"The role of glicentin and oxyntomodulin in human metabolism: new evidence and new directions","volume":"105","author":"Perakakis","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0265","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc19-0449","article-title":"Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes\/type 2 diabetes: a randomized, single-blinded, placebo-controlled study","volume":"42","author":"Behary","year":"2019","journal-title":"Diab Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0270","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2017-00469","article-title":"The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers","volume":"102","author":"Tan","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0275","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/dom.15028","article-title":"Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes\/diabetes but promotes restraint eating: a secondary analysis of a randomized single-blind placebo-controlled study","volume":"25","author":"Behary","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0280","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1210\/clinem\/dgab608","article-title":"The metabolomic effects of tripeptide gut hormone infusion compared to Roux-en-Y gastric bypass and caloric restriction","volume":"107","author":"Jones","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0285","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2023.155741_bb0290","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0295","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2023.155741_bb0300","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met\u00a0+\u00a0TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0305","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0310","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26\u00a0weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0315","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0325","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0330","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0\u00a0mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0335","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0340","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0345","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0350","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0355","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0360","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0365","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2023.155741_bb0370","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0375","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0380","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0385","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0390","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0395","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0400","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0405","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0410","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2337\/dbi21-0001","article-title":"The role of GIP receptor in the CNS for the pathogenesis of obesity","volume":"70","author":"Fukuda","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2023.155741_bb0415","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0420","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0425","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jgh3.12780","article-title":"Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: a pilot study","volume":"6","author":"Arai","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.metabol.2023.155741_bb0430","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0435","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4\u00a0mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2023.155741_bb0440","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-023-05929-0","article-title":"Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy","author":"Tschop","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2023.155741_bb0445","series-title":"Pharmacy times","article-title":"FDA approves label update for semaglutide, allowing use as first-line option for adults with type 2 diabetes","author":"Antrim","year":"2023"},{"key":"10.1016\/j.metabol.2023.155741_bb0450","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0455","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0460","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0465","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0470","first-page":"2011","article-title":"Oral Semaglutide led to similar weight loss as injection, company says","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0475","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0480","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2023.155741_bb0485","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2023.155741_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0500","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 receptor agonist orforglipron for adults with obesity","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215407","article-title":"Glucagon regulation of energy expenditure","volume":"20","author":"Kleinert","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2023.155741_bb0510","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2023.155741_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9\u00a0mg and 10\u00a0mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.metabol.2023.155741_bb0520","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1038\/s41467-022-31328-x","article-title":"A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2023.155741_bb0525","article-title":"Glucagon\/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues","author":"Martin Friedrichsen","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.metabol.2023.155741_bb0530","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0535","doi-asserted-by":"crossref","DOI":"10.1530\/JME-22-0168","article-title":"Cotadutide effect in liver and adipose tissue in obese mice","volume":"70","author":"Marcondes-de-Castro","year":"2023","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.metabol.2023.155741_bb0540","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0550","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/dom.14948","article-title":"Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor\/glucagon-like peptide-1 receptor agonist BI 456906","volume":"25","author":"Jungnik","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"Supplement_1","key":"10.1016\/j.metabol.2023.155741_bb0555","article-title":"A phase 2, randomized, double-blind, placebo-controlled, dose-finding study of BI 456906 in people with overweight\/obesity","volume":"72","author":"Le Roux","year":"2023","journal-title":"Diab Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0560","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0565","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0570","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0580","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0585","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0590","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2023.155741_bb0600","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/psc.3048","article-title":"GUB06-046, a novel secretin\/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice","volume":"23","author":"van Witteloostuijn","year":"2017","journal-title":"J Pept Sci"},{"key":"10.1016\/j.metabol.2023.155741_bb0605","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1021\/acs.jmedchem.0c01783","article-title":"Design and evaluation of peptide dual-agonists of GLP-1 and NPY2 receptors for glucoregulation and weight loss with mitigated nausea and emesis","volume":"64","author":"Milliken","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2023.155741_bb0610","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/dom.12390","article-title":"Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents","volume":"17","author":"Trevaskis","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0615","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.appet.2018.05.131","article-title":"A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice","volume":"127","author":"Hornigold","year":"2018","journal-title":"Appetite"},{"issue":"Supplement_1","key":"10.1016\/j.metabol.2023.155741_bb0620","article-title":"Dapiglutide, a once-weekly GLP-1R\/GLP-2R dual agonist, was safe and well tolerated and showed dose-dependent body weight loss over four weeks in healthy subjects","volume":"71","author":"Minna","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2023.155741_bb0625","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fnut.2017.00058","article-title":"Editorial: are rodent models fit for investigation of human obesity and related diseases?","volume":"4","author":"Even","year":"2017","journal-title":"Front Nutr"},{"key":"10.1016\/j.metabol.2023.155741_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2022.100208","article-title":"Of mice and men: considerations on adipose tissue physiology in animal models of obesity and human studies","volume":"15","author":"Lempesis","year":"2022","journal-title":"Metabol Open"},{"key":"10.1016\/j.metabol.2023.155741_bb0635","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnut.2016.00025","article-title":"The use of rat and mouse models in bariatric surgery experiments","volume":"3","author":"Lutz","year":"2016","journal-title":"Front Nutr"},{"key":"10.1016\/j.metabol.2023.155741_bb0640","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jamasurg.2016.2317","article-title":"Bariatric surgery and long-term durability of weight loss","volume":"151","author":"Maciejewski","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0645","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1007\/s11695-020-04788-7","article-title":"Impact of routine and long-term follow-up on weight loss after bariatric surgery","volume":"30","author":"Lujan","year":"2020","journal-title":"Obes Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0650","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.surg.2018.06.008","article-title":"Long-term weight change and health outcomes for sleeve gastrectomy (SG) and matched Roux-en-Y gastric bypass (RYGB) participants in the Longitudinal Assessment of Bariatric Surgery (LABS) study","volume":"164","author":"Ahmed","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.metabol.2023.155741_bb0655","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/jama.2022.9009","article-title":"Association of bariatric surgery with cancer risk and mortality in adults with obesity","volume":"327","author":"Aminian","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076192","article-title":"Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk","volume":"24","author":"Wilson","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2023.155741_bb0665","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"183","key":"10.1016\/j.metabol.2023.155741_bb0670","first-page":"4","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0675","unstructured":"SELECT: semaglutide reduces risk of MACE in adults with overweight or obesity. American College of Cardiology news story. https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2023\/08\/10\/14\/29\/SELECT-Semaglutide-Reduces-Risk-of-MACE-in-Adults-With-Overweight-or-Obesity. Accessed 15 September 2023."},{"key":"10.1016\/j.metabol.2023.155741_bb0680","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/obr.12294","article-title":"The impact of bariatric surgery on quality of life: a systematic review and meta-analysis","volume":"16","author":"Lindekilde","year":"2015","journal-title":"Obes Rev"},{"key":"10.1016\/j.metabol.2023.155741_bb0685","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031170","article-title":"Changes in quality of life 5\u00a0years after sleeve gastrectomy: a prospective cohort study","volume":"9","author":"Flolo","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.metabol.2023.155741_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cob.12226","article-title":"Improvements in health-related quality of life over 3\u00a0years with liraglutide 3.0\u00a0mg compared with placebo in participants with overweight or obesity","volume":"8","author":"Kolotkin","year":"2018","journal-title":"Clin Obes"},{"key":"10.1016\/j.metabol.2023.155741_bb0695","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/dom.14039","article-title":"Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)","volume":"22","author":"Jodar","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0700","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12871-018-0654-x","article-title":"Perioperative surgery- and anaesthesia-related risks of laparoscopic Roux-en-Y gastric bypass \u2014 a single centre, retrospective data analysis","volume":"18","author":"Schurner","year":"2018","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.metabol.2023.155741_bb0705","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/bjs\/znab245","article-title":"Perioperative mortality in bariatric surgery: meta-analysis","volume":"108","author":"Robertson","year":"2021","journal-title":"Br J Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0710","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13668-022-00400-9","article-title":"Nutritional deficiencies before and after bariatric surgery: prevention and treatment","volume":"11","author":"Argyrakopoulou","year":"2022","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.metabol.2023.155741_bb0715","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: a review","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0720","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like Peptide-1 receptor agonists for weight loss","volume":"e2319574","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2023.155741_bb0725","first-page":"A16","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","volume":"5","author":"John","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.metabol.2023.155741_bb0730","article-title":"Once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2023.155741_bb0735","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-8587(19)30157-3","article-title":"Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Miras","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2023.155741_bb0740","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1007\/s11695-022-06211-9","article-title":"The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery\u2014a retrospective analysis","volume":"32","author":"Lautenbach","year":"2022","journal-title":"Obes Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0745","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/oby.23736","article-title":"Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence","volume":"31","author":"Murvelashvili","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2023.155741_bb0750","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2023.2930","article-title":"Safety and efficacy of liraglutide, 3.0\u00a0mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial","author":"Mok","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0755","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4803","article-title":"Association of pre-operative body weight and weight loss with risk of death after bariatric surgery","volume":"3","author":"Sun","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2023.155741_bb0760","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0765","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4\u00a0mg with once-weekly semaglutide 2.4\u00a0mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0770","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0775","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cphy.c170055","article-title":"Glucagon-like peptide-2 and the regulation of intestinal growth and function","volume":"8","author":"Brubaker","year":"2018","journal-title":"Compr Physiol"},{"key":"10.1016\/j.metabol.2023.155741_bb0780","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.molmet.2013.12.001","article-title":"Action and therapeutic potential of oxyntomodulin","volume":"3","author":"Pocai","year":"2014","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0785","doi-asserted-by":"crossref","first-page":"308","DOI":"10.11613\/BM.2017.034","article-title":"Insights on glicentin, a promising peptide of the proglucagon family","volume":"27","author":"Raffort","year":"2017","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.metabol.2023.155741_bb0790","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1259\/0007-1285-48-573-691","article-title":"Pharmaco-radiology in barium examinations with special reference to glucagon","volume":"48","author":"Kreel","year":"1975","journal-title":"Br J Radiol"},{"key":"10.1016\/j.metabol.2023.155741_bb0795","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1113\/jphysiol.2008.164269","article-title":"The role of peptide YY in appetite regulation and obesity","volume":"587","author":"Karra","year":"2009","journal-title":"J Physiol"},{"key":"10.1016\/j.metabol.2023.155741_bb0800","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1007\/s00125-014-3292-y","article-title":"Peptide YY: more than just an appetite regulator","volume":"57","author":"Persaud","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2023.155741_bb0805","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/en.2015-1168","article-title":"Pancreatic PYY is critical in the control of insulin secretion and glucose homeostasis in female mice","volume":"156","author":"Shi","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2023.155741_bb0810","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1172\/JCI114425","article-title":"Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein","volume":"85","author":"Valet","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2023.155741_bb0815","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0820","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/21623945.2021.1945787","article-title":"Regulation of adipose tissue lipolysis by ghrelin is impaired with high-fat diet feeding and is not restored with exercise","volume":"10","author":"Hucik","year":"2021","journal-title":"Adipocyte"},{"key":"10.1016\/j.metabol.2023.155741_bb0825","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.2337\/db10-1088","article-title":"Final answer: ghrelin can suppress insulin secretion in humans, but is it clinically relevant?","volume":"59","author":"Meyer","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2023.155741_bb0830","doi-asserted-by":"crossref","first-page":"186","DOI":"10.14310\/horm.2002.1672","article-title":"Effects of ghrelin in energy balance and body weight homeostasis","volume":"15","author":"Mihalache","year":"2016","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.metabol.2023.155741_bb0835","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/gut.2004.062604","article-title":"Ghrelin: a new player in the control of gastrointestinal functions","volume":"54","author":"Peeters","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2023.155741_bb0840","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.737686","article-title":"Pleiotropic effects of secretin: a potential drug candidate in the treatment of obesity?","volume":"12","author":"Laurila","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2023.155741_bb0845","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s42255-021-00409-4","article-title":"Secretin activates brown fat and induces satiation","volume":"3","author":"Laurila","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0850","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.physbeh.2015.07.009","article-title":"Lipid transport in cholecystokinin knockout mice","volume":"151","author":"King","year":"2015","journal-title":"Physiol Behav"},{"key":"10.1016\/j.metabol.2023.155741_bb0855","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/db10-0789","article-title":"Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice","volume":"60","author":"Lo","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2023.155741_bb0860","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.684656","article-title":"Roles of cholecystokinin in the nutritional continuum. Physiology and potential therapeutics","volume":"12","author":"Miller","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2023.155741_bb0865","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-2007-1009195","article-title":"Cholecystokinin 1-21 stimulates lipolysis in human adipose tissue","volume":"21","author":"Richter","year":"1989","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.metabol.2023.155741_bb0870","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/SHK.0000000000001355","article-title":"Cholecystokinin modulates the mucosal inflammatory response and prevents the lipopolysaccharide-induced intestinal epithelial barrier dysfunction","volume":"53","author":"Saia","year":"2020","journal-title":"Shock"},{"key":"10.1016\/j.metabol.2023.155741_bb0875","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0880","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s11695-011-0479-x","article-title":"Randomized clinical trial of laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the management of patients with BMI\u00a0<\u00a050\u00a0kg\/m2","volume":"21","author":"Kehagias","year":"2011","journal-title":"Obes Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0885","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.2337\/dc12-1596","article-title":"Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment","volume":"36","author":"Kashyap","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0890","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(14)70066-X","article-title":"Multi-disciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial","volume":"2","author":"Wentworth","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2023.155741_bb0895","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s11695-014-1258-2","article-title":"A randomized clinical trial of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy for the treatment of morbid obesity in China: a 5-year outcome","volume":"24","author":"Zhang","year":"2014","journal-title":"Obes Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0900","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00125-016-3903-x","article-title":"Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial","volume":"59","author":"Cummings","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2023.155741_bb0905","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.soard.2016.08.025","article-title":"Ghrelin, leptin, and glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass\u2014results of a randomized clinical trial","volume":"13","author":"Kalinowski","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.metabol.2023.155741_bb0910","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes \u2014 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155741_bb0915","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/bjs.10400","article-title":"Randomized trial of Roux-en-Y gastric bypass versus sleeve gastrectomy in achieving excess weight loss","volume":"104","author":"Ignat","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0920","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jama.2017.20897","article-title":"Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial","volume":"319","author":"Peterli","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2023.155741_bb0925","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2337\/dc17-0487","article-title":"Clinical and patient-centered outcomes in obese patients with type 2 diabetes 3\u00a0years after randomization to Roux-en-Y gastric bypass surgery versus intensive lifestyle management: the SLIMM-T2D study","volume":"41","author":"Simonson","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155741_bb0930","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1210\/clinem\/dgaa006","article-title":"Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial","volume":"105","author":"Courcoulas","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155741_bb0935","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2023.155741_bb0940","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jamasurg.2022.2229","article-title":"Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10\u00a0years in adult patients with obesity: the SLEEVEPASS randomized clinical trial","volume":"157","author":"Salminen","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.metabol.2023.155741_bb0945","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dc21-2441","article-title":"Diabetes remission in the Alliance of Randomized Trials of Medicine versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D)","volume":"45","author":"Kirwan","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523003451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523003451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T02:32:57Z","timestamp":1731724377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049523003451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":187,"alternative-id":["S0026049523003451"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155741","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155741"}}